BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 2018;12:2665-75. [PMID: 30214155 DOI: 10.2147/DDDT.S101145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Mocking TAM, Buzink MCML, Leurs R, Vischer HF. Bioluminescence Resonance Energy Transfer Based G Protein-Activation Assay to Probe Duration of Antagonism at the Histamine H3 Receptor. Int J Mol Sci 2019;20:E3724. [PMID: 31366084 DOI: 10.3390/ijms20153724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Romigi A, Feola T, Cappellano S, De Angelis M, Pio G, Caccamo M, Testa F, Vitrani G, Centonze D, Colonnese C, Esposito V, Jaffrain-rea M. Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update. Front Neurol 2022;12:817257. [DOI: 10.3389/fneur.2021.817257] [Reference Citation Analysis]
3 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
4 Krahn LE, Zee PC, Thorpy MJ. Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know. Adv Ther 2022;39:221-43. [PMID: 34894325 DOI: 10.1007/s12325-021-01992-4] [Reference Citation Analysis]
5 Fabara SP, Ortiz JF, Anas Sohail A, Hidalgo J, Altamimi A, Tama B, Patel UK. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review. Cureus 2021;13:e16095. [PMID: 34345566 DOI: 10.7759/cureus.16095] [Reference Citation Analysis]
6 Watanabe M, Kobayashi T, Ito Y, Yamada S, Shuto S. Conformational Restriction of Histamine with a Rigid Bicyclo[3.1.0]hexane Scaffold Provided Selective H3 Receptor Ligands. Molecules 2020;25:E3562. [PMID: 32764432 DOI: 10.3390/molecules25163562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep 2019;42:zsz174. [PMID: 31529094 DOI: 10.1093/sleep/zsz174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
8 Inoue Y, Uchiyama M, Umeuchi H, Onishi K, Ogo H, Kitajima I, Matsushita I, Nishino I, Uchimura N. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials. BMC Psychiatry 2022;22:141. [PMID: 35193545 DOI: 10.1186/s12888-022-03785-7] [Reference Citation Analysis]
9 Rameau A, Hong RS, Djalilian H, Erbele ID, Phillips KM, Capasso R, Rose AS, Brenner MJ, Santa Maria PL. New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019. OTO Open 2020;4:2473974X20932506. [PMID: 32537556 DOI: 10.1177/2473974X20932506] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
11 Némethy Z, Kiss B, Lethbridge N, Chazot P, Hajnik T, Tóth A, Détári L, Schmidt É, Czurkó A, Kostyalik D, Oláh V, Hernádi I, Balázs O, Vizi ES, Ledneczki I, Mahó S, Román V, Lendvai B, Lévay G. Convergent cross-species pro-cognitive effects of RGH-235, a new potent and selective histamine H3 receptor antagonist/inverse agonist. Eur J Pharmacol 2021;:174621. [PMID: 34965389 DOI: 10.1016/j.ejphar.2021.174621] [Reference Citation Analysis]
12 Sarfraz N, Okuampa D, Hansen H, Alvarez M, Cornett EM, Kakazu J, Kaye AM, Kaye AD. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health Psychology Research 2022;10. [DOI: 10.52965/001c.34222] [Reference Citation Analysis]
13 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Reference Citation Analysis]
14 Alhusaini M, Eissa N, Saad AK, Beiram R, Sadek B. Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder. Front Pharmacol 2022;13:861094. [PMID: 35721194 DOI: 10.3389/fphar.2022.861094] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 . 薬理作用から見た理想的な抗ヒスタミン薬治療. Nippon Jibiinkoka Gakkai Kaiho 2019;123:196-204. [DOI: 10.3950/jibiinkoka.123.196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]